Objective In oncology, extrapolation of clinical outcomes beyond trial duration is traditionally
achieved by parametric survival analysis using population-level outcomes. This approach …

Background The immuno-oncologic (IO) mechanism of action may lead to an overall survival
(OS) hazard that changes over time, producing shapes that standard parametric …

Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients
with advanced renal cell carcinoma (RCC) from a US payer perspective. Methods A …

Objectives This analysis explores the impact of model selection on cost-effectiveness
analysis results using published clinical trial data in a flexible state transition (Markov) model …

Objectives To assess long-term survival outcomes for nivolumab plus ipilimumab (N+ I) and
sunitinib in renal cell carcinoma (RCC) predicted by two models: a partitioned survival …

Objectives Multiple database locks (DBLs) with different levels of data maturity have become
available for CheckMate-214 (NCT02231749), a phase 3 trial comparing nivolumab+ …

Objectives This analysis aimed to explore survival heterogeneity and estimate proportion of
potential long-term survivors (LTS) among previously untreated, I/P risk aRCC patients who …

Background Although several therapeutic options for patients with renal cell carcinoma
(RCC) have been approved over recent years, including immune checkpoint inhibitors …

Objectives CheckMate-214 (NCT02231749) is a phase 3 trial comparing the efficacy of
nivolumab in combination with ipilimumab (N+ I) to sunitinib among patients with previously …

Objectives Nivolumab+ ipilimumab is the only immuno-oncologic combination showing
significant and stable long-term clinical benefit compared with standard of care (sunitinib) in …